Participated · Seed · May 2026

Rogue produces protein-forward chips and puffs designed to deliver more than 10 grams of protein per serving while emphasizing ingredient transparency, active probiotics, and no seed oils or artificial ingredients. The brand balances flavor intensity and nutritional functionality and competes against legacy protein snack companies. Rogue was developed internally by Science Inc.’s venture studio and is positioning itself as a digital-first CPG brand with large-scale retail placement. It is preparing a nationwide Walmart launch to 2,800 stores in July and will begin online sales in early May, including a Walmart-exclusive Churro flavor among four SKUs. The company is building creator-driven marketing and commerce via TikTok Shop, Amazon, and a network of fitness and wellness creators to support DTC sales and brand awareness. Rogue raised $2.5 million in pre-seed funding to fund inventory, creator partnerships, and hires as it scales distribution.

Participated · Series A · May 2026

Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

Participated · Seed · May 2025

Final Boss Sour produces gaming-inspired sour snacks made from real dried fruits candied with a proprietary sour coating and without artificial colors or artificial fruit flavors. The Los Angeles-based brand launched in October 2023 and has pursued a social-first growth strategy driven by frequent product launches and creator collaborations. It has generated more than 2 billion organic video views across TikTok, YouTube and Instagram, built the largest YouTube subscriber base of any sour candy brand, and become the largest sour candy brand on TikTok Shop. The company has executed collaborations with cultural and sports figures including Trevor Zegras and Jazz Chisholm Jr., and brands such as PAC-MAN and G FUEL. Final Boss Sour is expanding into major retailers including Walmart, Kroger, H-E-B, Wegmans, Hy-Vee, with planned launches at Target and 7-Eleven, and has raised a total of $12 million to date to support product innovation, creator partnerships and national retail expansion.

Participated · Seed · Oct 2022

Dandi Technologies provides an analytics platform for advancing diversity, equity, and inclusion by aggregating and analyzing HR data across the employee lifecycle. The platform generates millions of DEI insights and offers intersectional measurement and sophisticated wage-gap analysis to pinpoint equity gaps and inform pay-equity actions. It integrates with leading HR systems including Workday, ADP, SAP, Oracle, Greenhouse and Taleo, and supplies real-time executive dashboards, visualizations, and custom-branded reports and slide exports. Led by CEO Jeff Fernandez and operating from New York City and Stockholm, Dandi helps businesses see how they recruit, retain, promote, and compensate employees. In October 2022 the company raised $3.7M in seed funding and added Courtney Leimkuhler of Springbank to its board. The company intends to use the proceeds to increase the number of people the platform positively impacts globally.

Participated · Series A · Mar 2022

Mytide's core product is the Gen2 platform, an AI-enabled, closed-loop manufacturing system that produces natural and non-natural peptides up to 30-times faster than traditional methods by integrating synthesis, analysis, purification, and lyophilization. The platform couples in-process data capture with a continuously learning AI engine to improve purity, production reliability, and speed while enabling access to difficult-to-manufacture non-canonical amino acids, constrained peptides, and short proteins. Mytide asserts it has built one of the largest and fastest-growing peptide manufacturing data repositories to support high-throughput screening, library generation, and computational biology modeling for in vivo, in vitro, and clinical studies. The company positions Gen2 for integration into cGMP environments to enable scalable, decentralized clinical-trial manufacturing of peptide-based therapeutics and personal peptide vaccines. Mytide has partnered with pharmaceutical companies for scalable, time-sensitive manufacturing across research and clinical programs. The recent financing is intended to scale the Gen2 platform and broaden access to cost-effective peptide and peptide-conjugate manufacturing.